

**Clinical trial results:****A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvanted with or without Monophosphoryl Lipid A and Aluminum Hydroxide in Adolescents and Adults****Summary**

EudraCT number	2013-001419-64
Trial protocol	BE
Global end of trial date	19 June 2015

Results information

Result version number	v1 (current)
This version publication date	04 July 2016
First version publication date	04 July 2016

Trial information**Trial identification**

Sponsor protocol code	NOR-107
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02038907
WHO universal trial number (UTN)	U1111-1147-3239

Notes:

Sponsors

Sponsor organisation name	Takeda Development Center Americas, Inc.
Sponsor organisation address	One Takeda Parkway, Deerfield, IL, United States, 60015
Public contact	Director, Clinical Science, Takeda, +1 877-825-3327, trialdisclosures@takeda.com
Scientific contact	Director, Clinical Science, Takeda, +1 877-825-3327, trialdisclosures@takeda.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 June 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	19 June 2015
Global end of trial reached?	Yes
Global end of trial date	19 June 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP) and MPL adjuvant (3-O-desacyl-4'-monophosphoryl lipid A) for further development.

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 March 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 420
Worldwide total number of subjects	420
EEA total number of subjects	420

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	420
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants took part in the study at 2 investigative sites in Belgium from 28 March 2014 (first participants signed the informed consent form) to 19 June 2015.

Pre-assignment

Screening details:

Healthy volunteers were enrolled equally in 1 of 14 unique formulation treatment groups: 11 formulation arms received 1 dose and 3 formulation arms received 2 doses.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	GI.1/GII.4 (15/15) - MPL (50)

Arm description:

Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.

Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Arm title	GI.1/GII.4 (15/50) - MPL (50)
------------------	-------------------------------

Arm description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.

Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:	
Hepatitis A vaccine, intramuscular injection (IM)	
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (50/50) - MPL (50)
Arm description:	
Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.	
Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Hepatitis A vaccine, intramuscular injection (IM)	
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (15/15) - MPL (15)
Arm description:	
Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.	
Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Hepatitis A vaccine, intramuscular injection (IM)	
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (15/50) - MPL (15)
Arm description:	
Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus	

VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.

Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Arm title	GI.1/GII.4 (50/50) - MPL (15)
------------------	-------------------------------

Arm description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.

Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Arm title	GI.1/GII.4 (15/15)
------------------	--------------------

Arm description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (15/50)
Arm description:	
Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.	
Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Hepatitis A vaccine, intramuscular injection (IM)	
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (50/50)
Arm description:	
Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.	
Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Hepatitis A vaccine, intramuscular injection (IM)	
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (50/150)
Arm description:	
Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.	
Arm type	Experimental

Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details: Hepatitis A vaccine, intramuscular injection (IM)	
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)
Arm description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.	
Arm type	Experimental
Investigational medicinal product name	Hepatitis A Vaccine
Investigational medicinal product code	
Other name	Havrix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details: Hepatitis A vaccine, intramuscular injection (IM)	
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (15/50) x2
Arm description: Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.	
Arm type	Experimental
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (50/150) x2
Arm description: Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.	
Arm type	Experimental

Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection	
Arm title	GI.1/GII.4 (15/50) - Al(OH) ₃ (167) x2

Arm description:

Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Arm type	Experimental
Investigational medicinal product name	Norovirus Bivalent Virus-Like Particle (VLP) Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Number of subjects in period 1	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)
Started	30	30	30
Completed	30	30	30
Not completed	0	0	0
Withdrawal by Subject	-	-	-
Protocol Violation	-	-	-

Number of subjects in period 1	GI.1/GII.4 (15/15) - MPL (15)	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)
Started	31	30	31
Completed	31	30	31
Not completed	0	0	0
Withdrawal by Subject	-	-	-
Protocol Violation	-	-	-

Number of subjects in period 1	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)	GI.1/GII.4 (50/50)
Started	30	32	29
Completed	30	32	29
Not completed	0	0	0
Withdrawal by Subject	-	-	-
Protocol Violation	-	-	-

Number of subjects in period 1	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Started	30	29	28

Completed	30	27	28
Not completed	0	2	0
Withdrawal by Subject	-	1	-
Protocol Violation	-	1	-

Number of subjects in period 1	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167) x2
Started	29	31
Completed	29	31
Not completed	0	0
Withdrawal by Subject	-	-
Protocol Violation	-	-

Baseline characteristics

Reporting groups

Reporting group title	GI.1/GII.4 (15/15) - MPL (50)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, IM on Day 28.

Reporting group title	GI.1/GII.4 (15/50) - MPL (50)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (50/50) - MPL (50)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/15) - MPL (15)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/50) - MPL (15)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (50/50) - MPL (15)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/15)
-----------------------	--------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/50)
-----------------------	--------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (50/50)
-----------------------	--------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (50/150)
-----------------------	---------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)
-----------------------	--

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/50) x2
-----------------------	-----------------------

Reporting group description:

Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted

with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Reporting group title	GI.1/GII.4 (50/150) x2
-----------------------	------------------------

Reporting group description:

Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Reporting group title	GI.1/GII.4 (15/50) - Al(OH) ₃ (167) x2
-----------------------	---

Reporting group description:

Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Reporting group values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)
Number of subjects	30	30	30
Age categorical Units: Subjects			
18-49 Years	15	14	15
50-64 Years	15	16	15
Age continuous Units: years			
median	50	51	50
full range (min-max)	19 to 63	20 to 64	22 to 64
Gender categorical Units: Subjects			
Female	18	20	20
Male	12	10	10
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	0	0
White	29	30	30
Region of Enrollment Units: Subjects			
Belgium	30	30	30
Height Units: cm			
median	173	167	166.5
full range (min-max)	156 to 187	154 to 193	153 to 191
Weight Units: kg			
median	69.5	65.6	70.6
full range (min-max)	49.4 to 105.2	49.1 to 103	50.8 to 104
Body Mass Index (BMI) Units: kg/m ²			
median	25.22	23.97	26.11
full range (min-max)	16.7 to 33.6	18.9 to 34.2	17.3 to 33.4

Reporting group values	GI.1/GII.4 (15/15) - MPL (15)	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)
Number of subjects	31	30	31

Age categorical Units: Subjects			
18-49 Years	15	15	15
50-64 Years	16	15	16
Age continuous Units: years			
median	50	49.5	50
full range (min-max)	20 to 64	20 to 64	20 to 64
Gender categorical Units: Subjects			
Female	22	19	23
Male	9	11	8
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	1	0	1
White	30	30	29
Region of Enrollment Units: Subjects			
Belgium	31	30	31
Height Units: cm			
median	167	171	169
full range (min-max)	149 to 187	155 to 186	153 to 190
Weight Units: kg			
median	66.6	71.6	68.5
full range (min-max)	42.2 to 103.3	47.6 to 101.9	44 to 96
Body Mass Index (BMI) Units: kg/m ²			
median	23.62	24.51	24.73
full range (min-max)	18.7 to 33.7	18.6 to 34.2	17.6 to 34.4

Reporting group values	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)	GI.1/GII.4 (50/50)
Number of subjects	30	32	29
Age categorical Units: Subjects			
18-49 Years	15	16	15
50-64 Years	15	16	14
Age continuous Units: years			
median	49.5	48.5	41
full range (min-max)	18 to 64	18 to 63	21 to 63
Gender categorical Units: Subjects			
Female	15	18	20
Male	15	14	9
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	1

White	30	32	28
Region of Enrollment Units: Subjects			
Belgium	30	32	29
Height Units: cm			
median	173.5	169.5	171
full range (min-max)	154 to 189	161 to 192	153 to 193
Weight Units: kg			
median	72.5	74.35	76
full range (min-max)	45.8 to 104.5	52 to 110.3	54.8 to 101.2
Body Mass Index (BMI) Units: kg/m ²			
median	24.4	24.06	26.06
full range (min-max)	18.1 to 33.7	17.8 to 33.2	19 to 34.6

Reporting group values	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Number of subjects	30	29	28
Age categorical Units: Subjects			
18-49 Years	15	15	14
50-64 Years	15	14	14
Age continuous Units: years			
median	51	49	48.5
full range (min-max)	20 to 63	21 to 62	23 to 64
Gender categorical Units: Subjects			
Female	23	16	16
Male	7	13	12
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	0	0
White	29	29	28
Region of Enrollment Units: Subjects			
Belgium	30	29	28
Height Units: cm			
median	167	172	171.5
full range (min-max)	153 to 186	156 to 199	161 to 192
Weight Units: kg			
median	69.85	70	75.5
full range (min-max)	50 to 92.6	49.6 to 94	42.5 to 92.5
Body Mass Index (BMI) Units: kg/m ²			
median	25.02	23.66	24.24
full range (min-max)	20 to 34.4	18.1 to 32.3	14.9 to 32.7

Reporting group values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167) x2	Total
Number of subjects	29	31	420
Age categorical			
Units: Subjects			
18-49 Years	15	16	210
50-64 Years	14	15	210
Age continuous			
Units: years			
median	48	44	
full range (min-max)	22 to 63	19 to 64	-
Gender categorical			
Units: Subjects			
Female	20	18	268
Male	9	13	152
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	0	0	5
White	29	31	414
Region of Enrollment			
Units: Subjects			
Belgium	29	31	420
Height			
Units: cm			
median	170	175	
full range (min-max)	153 to 187	146 to 192	-
Weight			
Units: kg			
median	70.6	69.9	
full range (min-max)	49.2 to 111.8	51 to 111.3	-
Body Mass Index (BMI)			
Units: kg/m ²			
median	23.19	24.54	
full range (min-max)	18.7 to 33.8	17.9 to 33.5	-

End points

End points reporting groups

Reporting group title	GI.1/GII.4 (15/15) - MPL (50)
Reporting group description: Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.	
Reporting group title	GI.1/GII.4 (15/50) - MPL (50)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (50/50) - MPL (50)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (15/15) - MPL (15)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (15/50) - MPL (15)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (50/50) - MPL (15)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (15/15)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (15/50)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (50/50)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (50/150)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)
Reporting group description: Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.	
Reporting group title	GI.1/GII.4 (15/50) x2
Reporting group description: Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted	

with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Reporting group title	GI.1/GII.4 (50/150) x2
-----------------------	------------------------

Reporting group description:

Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Reporting group title	GI.1/GII.4 (15/50) - Al(OH)3 (167) x2
-----------------------	---------------------------------------

Reporting group description:

Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Primary: Percentage of Participants With a Seroresponse (Pan-Ig ELISA)

End point title	Percentage of Participants With a Seroresponse (Pan-Ig)
-----------------	---

End point description:

Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and Day 56

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	31
Units: percentage of participants				
number (confidence interval 95%)	43.3 (25.5 to 62.6)	62.1 (42.3 to 79.3)	46.4 (27.5 to 66.1)	35.5 (19.2 to 54.6)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (confidence interval 95%)	80 (61.4 to 92.3)	67.7 (48.6 to 83.3)	30 (14.7 to 49.4)	62.5 (43.7 to 78.9)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH)3 (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	26	28

Units: percentage of participants				
number (confidence interval 95%)	42.9 (24.5 to 62.8)	66.7 (47.2 to 82.7)	46.2 (26.6 to 66.6)	71.4 (51.3 to 86.8)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: percentage of participants				
number (confidence interval 95%)	69 (49.2 to 84.7)	56.7 (37.4 to 74.5)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 1

End point title	Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 1 ^[2]
-----------------	--

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after each vaccination.

Safety population included all participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Days 1 through 7

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (not applicable)				
Pain	43.3	33.3	50	32.3
Erythema	0	0	0	0
Induration	0	0	0	0
Swelling	0	0	0	0

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
-------------------------	-------------------------------	-------------------------------	--------------------	--------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (not applicable)				
Pain	46.7	38.7	40	53.1
Erythema	0	0	0	0
Induration	0	0	0	0
Swelling	0	0	0	0

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (not applicable)				
Pain	44.8	53.3	48.3	46.4
Erythema	0	0	0	0
Induration	0	0	0	0
Swelling	3.4	0	0	0

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (not applicable)				
Pain	31	32.3		
Erythema	0	0		
Induration	0	0		
Swelling	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 2

End point title	Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 2 ^[3]
-----------------	--

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after each vaccination.

Safety population included all participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Days 28 through 34

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (not applicable)				
Pain	60	36.7	66.7	51.6
Erythema	0	0	3.3	0
Induration	0	0	3.3	0
Swelling	0	3.3	0	3.2

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (not applicable)				
Pain	53.3	58.1	33.3	43.8
Erythema	0	0	0	0
Induration	6.7	0	0	0
Swelling	0	3.2	0	0

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (not applicable)				
Pain	48.3	46.7	34.5	32.1
Erythema	3.4	3.3	0	0
Induration	3.4	3.3	0	0
Swelling	6.9	0	0	0

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
-------------------------	---------------------------	--	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (not applicable)				
Pain	41.4	35.5		
Erythema	0	0		
Induration	0	0		
Swelling	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 1

End point title	Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 1 ^[4]
-----------------	---

End point description:

Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after each vaccination.

Safety population included all participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Days 1 through 7

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (not applicable)				
Headache	20	26.7	3.3	19.4
Fatigue	23.3	23.3	16.7	19.4
Myalgia	20	6.7	13.3	6.5
Arthralgia	0	3.3	6.7	0
Vomiting	0	3.3	0	0
Diarrhea	0	23.3	3.3	16.1

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				

number (not applicable)				
Headache	16.7	12.9	13.3	25
Fatigue	10	12.9	13.3	15.6
Myalgia	3.3	9.7	6.7	18.8
Arthralgia	3.3	0	3.3	6.3
Vomitting	0	3.2	0	0
Diarrhea	20	6.5	13.3	12.5

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (not applicable)				
Headache	27.6	20	13.8	17.9
Fatigue	17.2	20	24.1	25
Myalgia	10.3	10	17.2	10.7
Arthralgia	6.9	3.3	3.4	3.6
Vomitting	0	3.3	3.4	0
Diarrhea	13.8	10	6.9	7.1

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (not applicable)				
Headache	31	19.4		
Fatigue	17.2	22.6		
Myalgia	3.4	19.4		
Arthralgia	3.4	3.2		
Vomitting	0	0		
Diarrhea	10.3	12.9		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 2

End point title	Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 2 ^[5]
-----------------	---

End point description:

Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea

that occurred within 7 days after each vaccination.

Safety population included all participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Days 28 through 34

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (not applicable)				
Headache	13.3	13.3	13.3	22.6
Fatigue	16.7	13.3	20	12.9
Myalgia	13.3	3.3	13.3	0
Arthralgia	0	3.3	3.3	0
Vomiting	0	0	0	0
Diarrhea	3.3	10	16.7	12.9

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (not applicable)				
Headache	23.3	16.1	10	21.9
Fatigue	10	12.9	10	18.8
Myalgia	13.3	12.9	0	6.3
Arthralgia	3.3	3.2	0	3.1
Vomiting	0	0	0	0
Diarrhea	16.7	9.7	6.7	15.6

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (not applicable)				
Headache	20.7	10	13.8	14.3
Fatigue	17.2	13.3	13.8	7.1
Myalgia	6.9	0	10.3	7.1
Arthralgia	0	3.3	3.4	3.6

Vomiting	0	3.3	3.4	0
Diarrhea	17.2	10	3.4	7.1

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants number (not applicable)				
Headache	34.5	19.4		
Fatigue	13.8	12.9		
Myalgia	0	6.5		
Arthralgia	0	3.2		
Vomiting	0	0		
Diarrhea	6.9	3.2		

Statistical analyses

No statistical analyses for this end point

Primary: Oral Body Temperature Within 7 Days After Dose 1

End point title	Oral Body Temperature Within 7 Days After Dose 1 ^[6]
-----------------	---

End point description:

Oral body temperature measurement is to be performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card also provided by the site.

Safety population included all participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Days 1 through 7

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	30
Units: degrees Celsius				
arithmetic mean (standard deviation)	36.54 (± 0.294)	36.76 (± 0.376)	36.66 (± 0.345)	36.71 (± 0.26)

End point values	GI.1/GII.4 (15/50) - MPL	GI.1/GII.4 (50/50) - MPL	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
------------------	-----------------------------	-----------------------------	-----------------------	-----------------------

	(15)	(15)		
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: degrees Celsius				
arithmetic mean (standard deviation)	36.65 (± 0.388)	36.67 (± 0.255)	36.74 (± 0.323)	36.63 (± 0.366)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: degrees Celsius				
arithmetic mean (standard deviation)	36.52 (± 0.405)	36.77 (± 0.341)	36.71 (± 0.404)	36.61 (± 0.368)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: degrees Celsius				
arithmetic mean (standard deviation)	36.7 (± 0.362)	36.61 (± 0.381)		

Statistical analyses

No statistical analyses for this end point

Primary: Oral Body Temperature Within 7 Days After Dose 2

End point title	Oral Body Temperature Within 7 Days After Dose 2 ^[7]
-----------------	---

End point description:

Oral body temperature measurement is to be performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card also provided by the site.

Safety population included all participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Days 28 through 34

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: degrees Celsius				
arithmetic mean (standard deviation)	36.54 (± 0.282)	36.76 (± 0.301)	36.68 (± 0.351)	36.75 (± 0.466)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: degrees Celsius				
arithmetic mean (standard deviation)	36.6 (± 0.286)	36.72 (± 0.317)	36.71 (± 0.394)	36.64 (± 0.342)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	27	28
Units: degrees Celsius				
arithmetic mean (standard deviation)	36.59 (± 0.463)	36.73 (± 0.293)	36.68 (± 0.345)	36.56 (± 0.351)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: degrees Celsius				
arithmetic mean (standard deviation)	36.76 (± 0.391)	36.61 (± 0.386)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Unsolicited Adverse Events (AEs)

End point title	Percentage of Participants With Unsolicited Adverse Events (AEs) ^[8]
-----------------	---

End point description:

Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study. Safety population included all participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 56

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (not applicable)	56.7	60	53.3	45.2

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (not applicable)	43.3	54.8	43.3	62.5

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (not applicable)	69	43.3	48.3	50

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (not applicable)	51.7	61.3		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Serious Adverse Events (SAEs)

End point title	Percentage of Participants With Serious Adverse Events
-----------------	--

End point description:

A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.

Safety population included all participants who received at least one dose of trial vaccine.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 393

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (not applicable)	6.7	0	16.7	6.5

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (not applicable)	3.3	0	10	9.4

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (not applicable)	3.4	3.3	3.4	7.1

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (not applicable)	3.4	3.2		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a Seroresponse on Day 28, Day 208 and Day 393 (Pan-Ig ELISA)

End point title	Percentage of Participants With a Seroresponse on Day 28, Day 208 and Day 393 (Pan-Ig ELISA)
-----------------	--

End point description:

Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). D=Day

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 28, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 11.6)	0 (0 to 11.6)	0 (0 to 11.9)	0 (0 to 11.2)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)	10 (2.1 to 26.5)	17.2 (5.8 to 35.8)	10 (2.1 to 26.5)	19.4 (7.5 to 37.5)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	17.2 (5.8 to 35.8)	20.7 (8 to 39.7)	13.3 (3.8 to 30.7)	16.1 (5.5 to 33.7)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (confidence interval 95%)				

D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 11.6)	0 (0 to 11.2)	0 (0 to 11.6)	0 (0 to 10.9)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)	20 (7.7 to 38.6)	20 (7.7 to 38.6)	6.7 (0.8 to 22.1)	34.4 (18.6 to 53.2)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	10 (2.1 to 26.5)	13.8 (3.9 to 31.7)	10.3 (2.2 to 27.4)	15.6 (5.3 to 32.8)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 12.3)	0 (0 to 11.6)	0 (0 to 12.8)	71.4 (51.3 to 86.8)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)	17.2 (5.8 to 35.8)	23.3 (9.9 to 42.3)	14.8 (4.2 to 33.7)	32.1 (15.9 to 52.4)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	6.9 (0.8 to 22.8)	13.3 (3.8 to 30.7)	7.4 (0.9 to 24.3)	21.4 (8.3 to 41)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	79.3 (60.3 to 92)	67.7 (48.6 to 83.3)		
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)	34.5 (17.9 to 54.3)	35.7 (18.6 to 55.9)		
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	20.7 (8 to 39.7)	20.7 (8 to 39.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in GI.1 VLP Antibody Titer (Pan-Ig ELISA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in GI.1
-----------------	--

End point description:

The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: percentage of participants number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 11.6)	0 (0 to 11.9)	0 (0 to 12.8)	6.9 (0.8 to 22.8)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	80 (61.4 to 92.3)	89.7 (72.6 to 97.8)	100 (87.7 to 100)	89.7 (72.6 to 97.8)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	60 (40.6 to 77.3)	65.5 (45.7 to 82.1)	67.9 (47.6 to 84.1)	72.4 (52.8 to 87.3)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	55.2 (35.7 to 73.6)	46.4 (27.5 to 66.1)	67.9 (47.6 to 84.1)	69 (49.2 to 84.7)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 11.6)	0 (0 to 11.2)	0 (0 to 11.6)	0 (0 to 10.9)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	93.3 (77.9 to 99.2)	96.8 (83.3 to 99.9)	86.7 (69.3 to 96.2)	87.5 (71 to 96.5)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	70 (50.6 to 85.3)	73.3 (54.1 to 87.7)	66.7 (47.2 to 82.7)	62.5 (43.7 to 78.9)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	63.3 (43.9 to 80.1)	65.5 (45.7 to 82.1)	55.2 (35.7 to 73.6)	53.1 (34.7 to 70.9)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 12.8)	0 (0 to 11.6)	4.2 (0.1 to 21.1)	85.7 (67.3 to 96)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	92.9 (76.5 to 99.1)	90 (73.5 to 97.9)	83.3 (62.6 to 95.3)	85.7 (67.3 to 96)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	85.7 (67.3 to 96)	60 (40.6 to 77.3)	54.2 (32.8 to 74.4)	71.4 (51.3 to 86.8)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	82.1 (63.1 to 93.9)	43.3 (25.5 to 62.6)	45.8 (25.6 to 67.2)	64.3 (44.1 to 81.4)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	93.1 (77.2 to 99.2)	93.3 (77.9 to 99.2)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	96.6 (82.2 to 99.9)	86.7 (69.3 to 96.2)		
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	75.9 (56.5 to 89.7)	74.1 (53.7 to 88.9)		
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	72.4 (52.8 to 87.3)	78.6 (59 to 91.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in GII.4 VLP Antibody Titer (Pan-Ig ELISA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in GII.4 VLP Antibody Titer (Pan-Ig ELISA)
-----------------	---

End point description:

The percentage of participants with a 4-fold rise or greater from in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 11.6)	0 (0 to 11.9)	0 (0 to 12.8)	0 (0 to 11.9)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	50 (31.3 to 68.7)	65.5 (45.7 to 82.1)	46.4 (27.5 to 66.1)	41.4 (23.5 to 61.1)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	16.7 (5.6 to 34.7)	27.6 (12.7 to 47.2)	7.1 (0.9 to 23.5)	27.6 (12.7 to 47.2)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	20.7 (8 to 39.7)	32.1 (15.9 to 52.4)	10.7 (2.3 to 28.2)	27.6 (12.7 to 47.2)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 11.6)	0 (0 to 11.2)	3.3 (0.1 to 17.2)	3.1 (0.1 to 16.2)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	83.3 (65.3 to 94.4)	71 (52 to 85.8)	33.3 (17.3 to 52.8)	71.9 (53.3 to 86.3)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	36.7 (19.9 to 56.1)	23.3 (9.9 to 42.3)	16.7 (5.6 to 34.7)	46.9 (29.1 to 65.3)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	20 (7.7 to 38.6)	17.2 (5.8 to 35.8)	17.2 (5.8 to 35.8)	21.9 (9.3 to 40)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 12.8)	3.3 (0.1 to 17.2)	0 (0 to 14.2)	78.6 (59 to 91.7)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	42.9 (24.5 to 62.8)	73.3 (54.1 to 87.7)	54.2 (32.8 to 74.4)	78.6 (59 to 91.7)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	14.3 (4 to 32.7)	30 (14.7 to 49.4)	16.7 (4.7 to 37.4)	35.7 (18.6 to 55.9)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	10.7 (2.3 to 28.2)	13.3 (3.8 to 30.7)	8.3 (1 to 27)	28.6 (13.2 to 48.7)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	86.2 (68.3 to 96.1)	70 (50.6 to 85.3)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	72.4 (52.8 to 87.3)	63.3 (43.9 to 80.1)		
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	41.4 (23.5 to 61.1)	33.3 (16.5 to 54)		
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	27.6 (12.7 to 47.2)	21.4 (8.3 to 41)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)

End point title	Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)
End point description:	Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. D=Day Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.
End point type	Secondary

End point timeframe:

Day 1 (Baseline) and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	833.4 (± 4.64)	790.3 (± 4.5)	636.7 (± 4.6)	647.6 (± 5.17)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	798.9 (± 4.66)	737.9 (± 4.42)	548.5 (± 4.47)	806.6 (± 5.36)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	14417.7 (± 2.74)	14171.3 (± 2.76)	17504.8 (± 2.64)	14220.4 (± 3.23)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	5725.2 (± 2.37)	5069.7 (± 2.48)	6084.3 (± 2.43)	5613.9 (± 2.68)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	3886 (± 2.98)	3179.7 (± 2.78)	4470.4 (± 2.55)	5009 (± 2.8)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	625.3 (± 2.96)	520.3 (± 4.99)	890.5 (± 4.75)	842.9 (± 4.92)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	573.6 (± 3.08)	514.6 (± 5.19)	910.4 (± 4.37)	821.5 (± 4.84)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	13982.2 (± 2.33)	18266 (± 1.99)	16082.5 (± 2.07)	15974.2 (± 3.95)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	4467.6 (± 2.05)	5106.4 (± 2.06)	5660.5 (± 2.22)	7174.8 (± 2.47)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	3209.6 (± 2.54)	3874.5 (± 2.55)	4940.3 (± 2.48)	4773.3 (± 2.62)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - AI	GI.1/GII.4 (15/50) x2
------------------	-----------------------	------------------------	----------------------------	--------------------------

			(OH)3 (167)	
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	677.2 (± 3.75)	827.3 (± 4.82)	856.7 (± 5.34)	741.5 (± 5.28)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	638.5 (± 3.9)	780.6 (± 5.11)	889.7 (± 5.34)	14488.6 (± 3)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	25808.9 (± 2.55)	154663 (± 2.59)	14045.2 (± 2.94)	12613.2 (± 2.46)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	7542 (± 2.28)	5361.1 (± 2.37)	5162.8 (± 2.18)	6863.9 (± 2.27)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	5550.1 (± 2.7)	3542.9 (± 2.54)	3960 (± 2.55)	4715.8 (± 2.51)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	897.5 (± 3.74)	742.7 (± 3.69)		
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	20839.2 (± 1.96)	15967.7 (± 2.39)		
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	17696.3 (± 1.92)	12235.7 (± 2.11)		
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	7459.1 (± 1.72)	5912.6 (± 1.94)		
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	5686.7 (± 2.17)	4404.7 (± 2.19)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)

End point title	Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)
-----------------	--

End point description:

Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.

D=Day

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (Baseline) and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	1106.6 (± 4.68)	1249.2 (± 3.45)	1477.7 (± 4.13)	1109.2 (± 4.1)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	1016.8 (± 5.56)	1232.6 (± 3.46)	1540.6 (± 3.83)	1110.4 (± 3.84)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	4595.7 (± 3)	8636.7 (± 2.05)	5750.4 (± 2.15)	4391.5 (± 2.66)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	2341.2 (± 3.93)	3653 (± 2.24)	2993.2 (± 3.61)	2887.7 (± 2.78)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	2236.5 (± 3.84)	3103 (± 3.03)	2450.2 (± 2.87)	2175.3 (± 2.91)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	921.7 (± 3.15)	1130.9 (± 4.18)	1340.4 (± 4.08)	1238.6 (± 3.92)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	839.4 (± 3.04)	1097.8 (± 4.14)	1268.1 (± 3.68)	1311 (± 3.98)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	7545.2 (± 2.61)	7802.7 (± 2.03)	3444.6 (± 2.92)	9945.7 (± 2.98)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	2984.6 (± 2.62)	3212.2 (± 2.44)	2251.1 (± 3.15)	5017.6 (± 2.82)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	1946.4 (± 2.51)	2173.7 (± 2.73)	2267.2 (± 3.29)	2969.9 (± 2.92)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	1201.2 (± 3.57)	1473.2 (± 3.88)	1832.3 (± 2.69)	977.7 (± 3.73)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	1139.9 (± 3.48)	1494.7 (± 3.05)	1924.8 (± 2.52)	8459.4 (± 2.19)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	5129.9 (± 2.91)	10624.2 (± 2.15)	10034.2 (± 1.96)	6622 (± 2.22)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	2615.1 (± 2.91)	4531.4 (± 2.21)	4667 (± 2.2)	3837.9 (± 2.3)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	1898.2 (± 3.41)	2550 (± 2.29)	2871.1 (± 2.43)	2425.1 (± 2.46)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	1324.4 (± 3.34)	1647 (± 3.39)		
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	12901.7 (± 2.12)	11116.3 (± 2.55)		
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	9995.5 (± 2.13)	8164 (± 2.32)		
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	4693.8 (± 2.52)	4546.8 (± 2.26)		
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	3133 (± 2.5)	3060.7 (± 2.44)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)

End point title	Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)
-----------------	--

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.13)	0.9 (± 1.18)	0.8 (± 1.5)	1.2 (± 2.85)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	17.3 (± 3.69)	18.8 (± 3.46)	25.8 (± 3.09)	22.4 (± 4.38)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	6.9 (± 3.63)	6.7 (± 3.71)	9.3 (± 3.77)	9 (± 4.32)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	4.4 (± 3.27)	4.1 (± 4.46)	7 (± 3.56)	8 (± 4.65)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.26)	1 (± 1.16)	1 (± 1.36)	1 (± 1.18)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	22.4 (± 3.02)	35.1 (± 3.88)	18.1 (± 4.35)	19 (± 3.67)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	7.1 (± 2.63)	10.4 (± 3.79)	6.4 (± 3.62)	8.5 (± 3.9)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	5.1 (± 2.41)	7.4 (± 3.36)	5.3 (± 3.4)	5.7 (± 3.41)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.28)	0.9 (± 1.28)	1 (± 1.58)	19.5 (± 3.73)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	36.5 (± 4.85)	18.7 (± 3.31)	13.5 (± 3.07)	17 (± 3.63)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	10.7 (± 3)	6.5 (± 2.96)	5.2 (± 3.27)	9.3 (± 3.57)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	7.8 (± 2.87)	4.3 (± 2.58)	4 (± 3.08)	6.4 (± 4.07)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	23.2 (± 3)	22 (± 2.57)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	19.7 (± 2.78)	16.8 (± 2.74)		
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	8.3 (± 2.79)	78 (± 3.52)		
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	6.3 (± 2.95)	6.1 (± 2.85)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)

End point title	Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)
-----------------	---

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
End point timeframe:	
Days 28, 56, 208 and 393	

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.56)	1 (± 1.14)	1 (± 1.23)	1 (± 1.21)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	4.2 (± 3.11)	7.2 (± 2.98)	4 (± 2.66)	4.1 (± 2.97)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	2.1 (± 2.45)	3 (± 2.74)	1.9 (± 1.96)	2.6 (± 2.5)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	1.9 (± 2.77)	2.6 (± 3.2)	1.7 (± 2.41)	2 (± 2.33)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.18)	1 (± 1.13)	0.9 (± 1.37)	1.1 (± 1.57)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	8.2 (± 2.72)	6.9 (± 3.31)	2.6 (± 2.6)	8 (± 3.36)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	3.2 (± 2.36)	2.7 (± 2.21)	1.7 (± 2.17)	4.1 (± 2.45)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	2.1 (± 2.34)	1.9 (± 1.99)	1.6 (± 2.46)	2.4 (± 2.4)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.17)	1 (± 1.58)	1 (± 1.25)	8.7 (± 3.25)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	4 (± 3)	7.2 (± 3.38)	4.7 (± 1.97)	6.8 (± 2.99)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	2 (± 2.06)	3.1 (± 2.61)	2.2 (± 1.92)	3.9 (± 2.7)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	1.5 (± 2.27)	1.7 (± 2.41)	1.4 (± 2.27)	2.5 (± 2.6)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	9.7 (± 3.02)	6.7 (± 3.11)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	7.5 (± 2.74)	5 (± 2.7)		
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	3.5 (± 2.24)	2.5 (± 2.57)		
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	2.4 (± 2.22)	1.7 (± 2.64)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP and GII.4 VLP Antibody Titers (IgA ELISA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP and GII.4 VLP Antibody Titers (IgA ELISA)
-----------------	--

End point description:

Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56. D=Day

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 11.6)	0 (0 to 11.6)	0 (0 to 11.9)	0 (0 to 11.2)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	53.3 (34.3 to 71.7)	58.6 (38.9 to 76.5)	39.3 (21.5 to 59.4)	45.2 (27.3 to 64)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 11.6)	0 (0 to 11.2)	3.03 (0.1 to 17.2)	0 (0 to 10.9)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	70 (50.6 to 85.3)	58.1 (39.1 to 75.5)	36.7 (19.9 to 56.1)	65.6 (46.8 to 81.4)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 12.3)	0 (0 to 11.6)	0 (0 to 12.8)	71.4 (51.3 to 86.8)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	42.9 (24.5 to 62.8)	66.7 (47.2 to 82.7)	50 (29.9 to 70.1)	57.1 (37.2 to 75.5)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	72.4 (52.8 to 87.3)	64.5 (45.4 to 80.8)		
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	51.7 (32.5 to 70.6)	46.7 (28.3 to 65.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP and GII.4 VLP Antibody Titers (IgA ELISA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP and GII.4 VLP Antibody Titers (IgA ELISA) ^[10]
-----------------	--

End point description:

Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for selected arms on day 208 and day 393. D=Day

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 208 and 393

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: percentage of participants				
number (confidence interval 95%)				
D208 (n=30,32)	30 (14.7 to 49.4)	25 (11.5 to 43.4)		
D393 (n=30,31)	13.3 (3.8 to 30.7)	6.5 (0.8 to 21.4)		

Statistical analyses

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (IgA ELISA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (IgA ELISA)
-----------------	--

End point description:

The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56. D=Day
Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 11.6)	0 (0 to 11.9)	0 (0 to 12.8)	6.9 (0.8 to 22.8)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	93.3 (77.9 to 99.2)	89.7 (72.6 to 97.8)	100 (87.7 to 100)	89.7 (72.6 to 97.8)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 11.6)	0 (0 to 11.2)	3.3 (0.1 to 17.2)	0 (0 to 10.9)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	96.7 (82.8 to 99.9)	100 (88.8 to 100)	90 (73.5 to 97.9)	90.6 (75 to 98)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
------------------	-----------------------	------------------------	--	--------------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 12.8)	0 (0 to 11.6)	4.2 (0.1 to 21.1)	96.4 (81.7 to 99.9)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	96.4 (81.7 to 99.9)	100 (88.4 to 100)	87.5 (67.6 to 97.3)	96.4 (81.7 to 99.9)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	100 (88.1 to 100)	100 (88.4 to 100)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	100 (88.1 to 100)	100 (88.4 to 100)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (IgA ELISA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (IgA ELISA) ^[11]
-----------------	--

End point description:

The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for selected arms on day 208 and day 393. D=Day
Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 208 and 393

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: percentage of participants				
number (confidence interval 95%)				
D208 (n=30,32)	80 (61.4 to 92.3)	71.9 (53.3 to 86.3)		
D393 (n=30,31)	73.3 (54.1 to 87.7)	54.8 (36 to 72.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (IgA ELISA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (IgA ELISA)
-----------------	---

End point description:

The percentage of participants with a 4-fold rise from or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56. D=Day
Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,2	0 (0 to 11.6)	0 (0 to 11.9)	0 (0 to 12.8)	0 (0 to 11.7)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,2	53.3 (34.3 to 71.7)	65.5 (45.7 to 82.1)	39.3 (21.5 to 59.4)	51.7 (32.5 to 70.6)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
-------------------------	-------------------------------------	-------------------------------------	-----------------------	-----------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,2)	0 (0 to 11.9)	0 (0 to 11.2)	3.3 (0.1 to 17.2)	3.1 (0.1 to 16.2)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,2)	73.3 (54.1 to 87.7)	58.1 (39.1 to 75.5)	36.7 (19.9 to 56.1)	68.8 (50 to 83.9)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH)3 (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,2)	0 (0 to 12.8)	3.3 (0.1 to 17.2)	0 (0 to 14.2)	75 (55.1 to 89.3)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,2)	46.4 (27.5 to 66.1)	66.7 (47.2 to 82.7)	54.2 (32.8 to 74.4)	60.7 (40.6 to 78.5)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,2)	72.4 (52.8 to 87.3)	63.3 (43.9 to 80.1)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,2)	51.7 (32.5 to 70.6)	46.7 (28.3 to 65.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (IgA ELISA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (IgA ELISA) ^[12]
-----------------	---

End point description:

The percentage of participants with a 4-fold rise from or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for selected arms on day 208 and day 393. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 208 and 393

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: percentage of participants				
number (confidence interval 95%)				
D208 (n=30,32)	36.7 (19.9 to 56.1)	34.4 (18.6 to 53.2)		
D393 (n=30,31)	23.3 (9.9 to 42.3)	16.1 (5.5 to 33.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (IgA ELISA)

End point title	Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (IgA ELISA)
-----------------	--

End point description:

Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56. D=Day

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (Baseline) and Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	52.9 (± 4.86)	37.4 (± 3.59)	42.1 (± 3.63)	32.1 (± 5.26)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	48.9 (± 4.99)	34.6 (± 3.38)	41.2 (± 3.85)	41 (± 4.38)

D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	1358.4 (± 4.02)	996.2 (± 5.02)	2223.3 (± 2.91)	1068.7 (± 5.39)
--	-----------------	----------------	-----------------	-----------------

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	30.1 (± 3.26)	44.5 (± 6.06)	53.6 (± 5.76)	60.1 (± 6.45)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	29.4 (± 3.31)	46.2 (± 6.22)	54.4 (± 5.67)	59.8 (± 6.23)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	1368.6 (± 3.99)	1849.8 (± 3.35)	1594.9 (± 4.87)	1435.5 (± 7.02)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	36.8 (± 5.3)	58.5 (± 4.08)	47 (± 4.91)	73.3 (± 5.24)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	37.8 (± 5.2)	56.3 (± 3.95)	57 (± 5.31)	1649.9 (± 4.88)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	2074.3 (± 4.4)	1510.6 (± 4.45)	1131.2 (± 4.28)	810.7 (± 5.58)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	40.8 (± 4.25)	41.5 (± 3.74)		
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	2148.2 (± 2.98)	1703.2 (± 2.62)		

D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	922.6 (± 3.73)	848.2 (± 3.63)		
--	----------------	----------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (IgA ELISA)

End point title	Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (IgA ELISA) ^[13]
-----------------	--

End point description:

Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for selected arms on day 208 and day 393. D=Day

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (Baseline) and Days 208 and 393

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
D208 (n=30,32)	302.5 (± 4.1)	512.4 (± 5.85)		
D393 (n=30,31)	224 (± 2.73)	340.1 (± 3.91)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (IgA ELISA)

End point title	Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (IgA ELISA)
-----------------	---

End point description:

Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56. D=Day

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (Baseline) and Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	83.4 (± 6.63)	113.6 (± 4.43)	145.5 (± 4.72)	119.5 (± 4.47)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	77.8 (± 6.49)	110 (± 4.31)	151.2 (± 4.7)	125.3 (± 4.34)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	495.7 (± 3.3)	840.8 (± 2.87)	583.7 (± 2.34)	467.9 (± 2.79)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	72.8 (± 4.64)	114.6 (± 4.56)	100.2 (± 4.47)	133 (± 4.77)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	73.8 (± 4.42)	116.3 (± 4.49)	106.3 (± 4.05)	139.2 (± 5.48)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	803.3 (± 3.24)	714.2 (± 2.44)	336.7 (± 3.74)	1088.9 (± 3.72)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	114.3 (± 4.65)	158.5 (± 3.41)	201.7 (± 3.3)	105.9 (± 4.08)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	106.3 (± 4.71)	164.8 (± 3.16)	218.8 (± 3.07)	953.5 (± 2.83)

D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	513.9 (± 3.82)	1117.7 (± 3.03)	1027.3 (± 2.36)	578.8 (± 3.11)
--	----------------	-----------------	-----------------	----------------

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	121.9 (± 4.16)	174.5 (± 4.13)		
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	948.2 (± 2.52)	1118 (± 2.91)		
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	552.2 (± 2.6)	691.2 (± 3.12)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (IgA ELISA)

End point title	Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (IgA ELISA) ^[14]
-----------------	---

End point description:

Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for selected arms on day 208 and day 393. D=Day

Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 208 and 393

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
D208 (n=30,32)	251.8 (± 3.94)	427.9 (± 3.95)		
D393 (n=30,31)	139.7 (± 4.07)	273.4 (± 3.59)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (IgA ELISA)

End point title	Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (IgA ELISA)
-----------------	---

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56. D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.52)	0.9 (± 1.49)	1 (± 1.23)	1.3 (± 2.65)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	25.7 (± 4.46)	28 (± 4.4)	49.2 (± 2.81)	34.2 (± 5.55)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.23)	1 (± 1.14)	1 (± 1.44)	1 (± 1.1)

D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	45.4 (± 3.47)	41.5 (± 3.5)	29.8 (± 4.63)	23.9 (± 4.13)
--	---------------	--------------	---------------	---------------

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.13)	1 (± 1.46)	1.2 (± 1.86)	22.5 (± 2.95)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	52.1 (± 3.61)	25.8 (± 3.15)	20.8 (± 2.77)	11.1 (± 2.19)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	52.7 (± 2.79)	42.3 (± 2.39)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	22.6 (± 2.29)	21.1 (± 2.81)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (IgA ELISA)

End point title	Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (IgA ELISA) ^[15]
-----------------	---

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for selected arms on day 208 and day 393. D=Day
Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 208 and 393

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: ratio				
geometric mean (standard deviation)				
D208 (n=30,32)	10 (± 2.89)	8.5 (± 3.77)		
D393 (n=30,31)	7.4 (± 2.41)	5.2 (± 3.34)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (IgA ELISA)

End point title	Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (IgA ELISA)
-----------------	--

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56. D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.33)	1 (± 1.42)	1 (± 1.13)	1.1 (± 1.27)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	5.9 (± 4.37)	7.7 (± 3.92)	3.6 (± 2.45)	4.2 (± 2.54)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.14)	1 (± 1.09)	1.1 (± 1.44)	1 (± 1.6)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	11 (± 3.48)	6.2 (± 3.36)	3.4 (± 2.7)	8.2 (± 3.36)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.1)	1 (± 1.36)	1 (± 1.22)	9 (± 2.85)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	4 (± 3.14)	7.1 (± 2.81)	4.9 (± 2.35)	5.5 (± 4.74)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: ratio				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	7.8 (± 2.89)	6.3 (± 3.11)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	4.5 (± 2.53)	3.9 (± 2.41)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (IgA ELISA)

End point title	Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (IgA ELISA) ^[16]
-----------------	--

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for selected arms on day 208 and day 393. D=Day
Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type Secondary

End point timeframe:

Days 208 and 393

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: ratio				
geometric mean (standard deviation)				
D208 (n=30,32)	3.5 (± 2.67)	3.2 (± 2.44)		
D393 (n=30,31)	1.9 (± 2.47)	1.9 (± 2.26)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP(HBGA)

End point title Percentage of Participants With a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP(HBGA)

End point description:

Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay. D=Day
Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type Secondary

End point timeframe:

Baseline and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (confidence interval 95%)				

D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 11.6)	0 (0 to 11.6)	0 (0 to 11.9)	0 (0 to 11.2)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	33.3 (17.3 to 52.8)	55.2 (35.7 to 73.6)	32.1 (15.9 to 52.4)	35.5 (19.2 to 54.6)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)	10 (2.1 to 26.5)	20.7 (8 to 39.7)	16.7 (5.6 to 34.7)	6.5 (0.8 to 21.4)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)	3.4 (0.1 to 17.8)	13.8 (3.9 to 31.7)	6.7 (0.8 to 22.1)	3.2 (0.1 to 16.7)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 11.6)	0 (0 to 11.2)	0 (0 to 11.6)	0 (0 to 10.9)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	66.7 (47.2 to 82.7)	51.6 (33.1 to 69.8)	26.7 (12.3 to 45.9)	59.4 (40.6 to 76.3)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)	13.3 (3.8 to 30.7)	13.3 (3.8 to 30.7)	20 (7.7 to 38.6)	31.3 (16.1 to 50)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)	6.7 (0.8 to 22.1)	3.4 (0.1 to 17.8)	6.9 (0.8 to 22.8)	9.4 (2 to 25)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	0 (0 to 12.3)	0 (0 to 11.6)	0 (0 to 12.8)	67.9 (47.6 to 84.1)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	28.6 (13.2 to 48.7)	60 (40.6 to 77.3)	53.8 (33.4 to 73.4)	75 (55.1 to 89.3)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)	20.7 (8 to 39.7)	16.7 (5.6 to 34.7)	7.4 (0.9 to 24.3)	42.9 (24.5 to 62.8)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)	3.4 (0.1 to 17.8)	3.3 (0.1 to 17.2)	3.7 (0.1 to 19)	7.1 (0.9 to 23.5)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	62.1 (42.3 to 79.3)	67.7 (48.6 to 83.3)		
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	58.6 (38.9 to 76.5)	56.7 (37.4 to 74.5)		
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)	34.5 (17.9 to 54.3)	21.4 (8.3 to 41)		
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)	10.3 (2.2 to 27.4)	7.1 (0.9 to 23.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)
-----------------	---

End point description:

The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay. D=Day
Per-Protocol Set included all participants who received both doses of study drug and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 11.6)	0 (0 to 11.9)	0 (0 to 12.8)	0 (0 to 11.9)

D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	80 (61.4 to 92.3)	79.3 (60.3 to 92)	85.7 (67.3 to 96)	82.8 (64.2 to 94.2)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	53.3 (34.3 to 71.7)	65.5 (45.7 to 82.1)	67.9 (47.6 to 84.1)	58.6 (38.9 to 76.5)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	31 (15.3 to 50.8)	32.1 (15.9 to 52.4)	50 (30.6 to 69.4)	37.9 (20.7 to 57.7)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 11.6)	0 (0 to 11.2)	0 (0 to 11.6)	0 (0 to 10.9)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	86.7 (69.3 to 96.2)	87.1 (70.2 to 96.4)	76.7 (57.7 to 90.1)	78.1 (60 to 90.7)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	43.3 (25.5 to 62.6)	70 (50.6 to 85.3)	60 (40.6 to 77.3)	78.1 (60 to 90.7)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	23.3 (9.9 to 42.3)	37.9 (20.7 to 57.7)	44.8 (26.4 to 64.3)	53.1 (34.7 to 70.9)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0 (0 to 12.8)	0 (0 to 11.6)	0 (0 to 14.2)	82.1 (63.1 to 93.9)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	85.7 (67.3 to 96)	90 (73.5 to 97.9)	70.8 (48.9 to 87.4)	100 (87.7 to 100)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	82.1 (63.1 to 93.9)	56.7 (37.4 to 74.5)	33.3 (15.6 to 55.3)	85.7 (67.3 to 96)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	53.6 (33.9 to 72.5)	26.7 (12.3 to 45.9)	29.2 (12.6 to 51.1)	50 (30.6 to 69.4)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al		

		(OH)3 (167) x2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	96.6 (82.2 to 99.9)	93.3 (77.9 to 99.2)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	96.6 (82.2 to 99.9)	93.3 (77.9 to 99.2)		
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	93.1 (77.2 to 99.2)	77.8 (57.7 to 91.4)		
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	51.7 (32.5 to 70.6)	46.4 (27.5 to 66.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)

End point title	Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)
End point description:	The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay. D=Day Per-Protocol Set included all participants who received both doses of study drug and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.
End point type	Secondary
End point timeframe:	Baseline and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	3.3 (0.1 to 17.2)	0 (0 to 11.9)	3.7 (0.1 to 19)	0 (0 to 11.9)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	46.7 (28.3 to 65.7)	72.4 (52.8 to 87.3)	39.3 (21.5 to 59.4)	41.4 (23.5 to 61.1)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	26.7 (12.3 to 45.9)	31 (15.3 to 50.8)	17.9 (6.1 to 36.9)	20.7 (8 to 39.7)

D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	13.8 (3.9 to 31.7)	21.4 (8.3 to 41)	3.6 (0.1 to 18.3)	17.2 (5.8 to 35.8)
---	--------------------	------------------	-------------------	--------------------

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	3.3 (0.1 to 17.2)	0 (0 to 11.2)	0 (0 to 11.6)	3.1 (0.1 to 16.2)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	80 (61.4 to 92.3)	61.3 (42.2 to 78.2)	26.7 (12.3 to 45.9)	71.9 (53.3 to 86.3)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	43.3 (25.5 to 62.6)	20 (7.7 to 38.6)	20 (7.7 to 38.6)	43.8 (26.4 to 62.3)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	23.3 (9.9 to 42.3)	3.4 (0.1 to 17.8)	10.3 (2.2 to 27.4)	12.5 (3.5 to 29)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: percentage of participants				
number (confidence interval 95%)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	3.7 (0.1 to 19)	3.3 (0.1 to 17.2)	0 (0 to 14.2)	82.1 (63.1 to 93.9)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	35.7 (18.6 to 55.9)	63.3 (43.9 to 80.1)	66.7 (44.7 to 84.4)	75 (55.1 to 89.3)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	21.4 (8.3 to 41)	33.3 (17.3 to 52.8)	25 (9.8 to 46.7)	50 (30.6 to 69.4)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	10.7 (2.3 to 28.2)	16.7 (5.6 to 34.7)	4.2 (0.1 to 21.1)	21.4 (8.3 to 41)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: percentage of participants				
number (confidence interval 95%)				

D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	65.5 (45.7 to 82.1)	70 (50.6 to 85.3)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	58.6 (38.9 to 76.5)	60 (40.6 to 77.3)		
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	37.9 (20.7 to 57.7)	22.2 (8.6 to 42.3)		
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	24.1 (10.3 to 43.5)	10.7 (2.3 to 28.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)

End point title	Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)
-----------------	---

End point description:

Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
D=Day

Full Analysis Set included all participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	24.8 (± 2.75)	18.7 (± 1.85)	26 (± 2.73)	26.8 (± 3.35)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	25 (± 2.6)	18.6 (± 1.86)	23.8 (± 2.44)	26.7 (± 3.19)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	280.5 (± 3.94)	236.3 (± 4.61)	403.3 (± 3.74)	286.9 (± 5.01)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	130 (± 3.38)	98.2 (± 3.46)	159 (± 3.23)	136.4 (± 3.67)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	67.8 (± 3.78)	51.3 (± 3.23)	88.1 (± 6.54)	74.8 (± 4.26)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	19.1 (± 1.68)	24.8 (± 2.31)	30.5 (± 3.04)	24.5 (± 2.59)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	18.6 (± 1.7)	23 (± 2.24)	27.3 (± 2.46)	25.1 (± 2.52)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	22.86 (± 3.94)	356.4 (± 3.74)	400.1 (± 3.33)	412.9 (± 4.78)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	80.1 (± 3.49)	139.3 (± 2.68)	159.8 (± 2.73)	202.1 (± 3.34)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	44 (± 3.39)	71.9 (± 3.4)	91.5 (± 3.14)	107.5 (± 3.97)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	23.8 (± 2.46)	23.2 (± 2.19)	26.3 (± 2.68)	23.1 (± 2.25)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	25.5 (± 2.52)	24.8 (± 2.37)	28.5 (± 2.66)	347.6 (± 4.62)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	510 (± 4.36)	247.2 (± 3.43)	271.3 (± 5)	398.6 (± 2.7)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	208.6 (± 3.28)	114.5 (± 2.89)	107.9 (± 3.28)	196.4 (± 2.86)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	99.6 (± 4.09)	55 (± 3.22)	66.1 (± 3.86)	103.4 (± 3.95)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		

Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	22.3 (± 2.26)	20.6 (± 2.04)		
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	385.9 (± 3.64)	391.1 (± 3.56)		
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	463.5 (± 2.32)	355.8 (± 2.58)		
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	219.2 (± 2.29)	182 (± 2.4)		
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)	113.6 (± 3.3)	81 (± 2.85)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of GII.4 VLP Antibody Titers (HBGA)

End point title	Blocking Titers 50 (BT50) of GII.4 VLP Antibody Titers (HBGA)
End point description:	Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay. D=Day Full Analysis Set included all participants who received at least one dose of trial vaccine. "n" in the category is the number of participants with data available at the given time-point.
End point type	Secondary
End point timeframe:	Day 1 (Baseline) and Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	66 (± 4.85)	80.1 (± 3.44)	115.3 (± 4.24)	91.4 (± 4.15)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	69.3 (± 4.56)	75.7 (± 3.63)	124.9 (± 3.98)	87.9 (± 3.75)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	336.9 (± 3.4)	686.3 (± 3.47)	429 (± 2.4)	317.8 (± 2.94)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	186.7 (± 3.19)	241.5 (± 3.24)	244.6 (± 2.78)	206.3 (± 2.84)

D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)	120.5 (± 4.21)	180.2 (± 3.95)	123.5 (± 3.87)	133.2 (± 3.81)
---	----------------	----------------	----------------	----------------

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	60.9 (± 3.84)	96.6 (± 4.03)	80.7 (± 4.48)	89.8 (± 4.41)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	67.7 (± 3.76)	94.5 (± 4.3)	74.6 (± 4.17)	98.1 (± 5.11)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	675.7 (± 3.21)	632.1 (± 2.11)	189.2 (± 4.63)	842.8 (± 3.23)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	229.9 (± 3.6)	259.7 (± 2.66)	142.5 (± 4.09)	346.8 (± 2.92)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)	104.7 (± 4.01)	134.4 (± 3.74)	109.3 (± 4.44)	182.9 (± 3.6)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	96.2 (± 3.93)	102.3 (± 3.39)	121.9 (± 3.47)	56.1 (± 3.48)
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	92.9 (± 3.87)	123.3 (± 3.25)	117.6 (± 3.62)	552.6 (± 3.65)
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	360.1 (± 3.85)	862.8 (± 3.12)	778 (± 2.57)	426.5 (± 3.46)
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	201 (± 3.49)	340.6 (± 2.6)	324.6 (± 3.07)	277.5 (± 2.53)
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)	121.9 (± 3.88)	179.7 (± 2.53)	209 (± 3.38)	126.2 (± 3.56)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al		

		(OH)3 (167) x2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)	92 (± 3.96)	117.8 (± 3.91)		
D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)	688.4 (± 3.16)	904.4 (± 2.67)		
D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)	596.3 (± 2.86)	604.4 (± 2.91)		
D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)	350.9 (± 2.36)	295.3 (± 3.07)		
D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)	171.2 (± 3.61)	192.9 (± 3.52)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)

End point title	Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)
End point description:	Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.
End point type	Secondary
End point timeframe:	Days 28, 56, 208 and 393

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.3)	1 (± 1.08)	0.9 (± 1.3)	1 (± 1.21)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	11.3 (± 4.25)	13.2 (± 4.31)	14.9 (± 3.54)	10 (± 4.07)

D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	5.2 (± 3.41)	5.5 (± 3.18)	6 (± 2.97)	4.8 (± 2.91)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	2.7 (± 3.29)	2.7 (± 2.71)	3.3 (± 2.87)	2.6 (± 2.97)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.37)	0.9 (± 1.26)	0.9 (± 1.59)	1 (± 1.22)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	12 (± 3.36)	14.3 (± 2.98)	13.1 (± 3.96)	16.9 (± 4.6)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	4.2 (± 2.94)	5.9 (± 2)	5.2 (± 2.69)	8.2 (± 3.14)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	2.3 (± 2.65)	3 (± 2.35)	2.9 (± 2.61)	4.4 (± 3.3)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1.1 (± 1.37)	1.1 (± 1.28)	1 (± 1.31)	15 (± 3.8)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	21.1 (± 3.72)	10.7 (± 2.53)	9.7 (± 4.29)	17.2 (± 2.36)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	8.6 (± 2.63)	4.9 (± 2.24)	3.7 (± 2.95)	8.5 (± 2.52)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	4 (± 3.1)	2.4 (± 2.35)	2.4 (± 2.73)	4.5 (± 3.29)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		

Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	17.3 (± 3.02)	19.3 (± 3.33)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	20.8 (± 2.2)	17.9 (± 2.68)		
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	9.8 (± 2.18)	7.9 (± 2.21)		
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	5.1 (± 2.81)	3.8 (± 2.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)

End point title	Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)
-----------------	---

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA binding assay. D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1.1 (± 1.68)	0.9 (± 1.59)	1 (± 1.47)	1 (± 1.73)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	5.1 (± 4.42)	8.9 (± 3.31)	3.6 (± 2.71)	3.7 (± 3.43)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	2.8 (± 3.1)	3.1 (± 2.51)	2 (± 2.42)	2.4 (± 2.58)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	1.7 (± 3.14)	2.3 (± 2.42)	1 (± 2.43)	1.5 (± 2.56)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1.1 (± 1.62)	1 (± 1.38)	0.9 (± 1.29)	1.1 (± 1.89)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	11.1 (± 3.32)	6.5 (± 3.33)	2.3 (± 2.95)	9.4 (± 3.95)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	3.8 (± 2.56)	2.5 (± 1.99)	1.8 (± 2.27)	3.9 (± 3.03)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	1.7 (± 2.32)	1.4 (± 1.82)	1.3 (± 2.25)	2 (± 2.59)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.59)	1.2 (± 2.45)	1 (± 1.46)	9.8 (± 3.48)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	3.5 (± 3.61)	8.4 (± 3.59)	6 (± 2.24)	7.6 (± 3.19)
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	2 (± 2.3)	3.3 (± 2.66)	2.5 (± 1.73)	4.9 (± 2.72)
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	1.3 (± 2.28)	1.8 (± 2.11)	1.6 (± 1.9)	2.2 (± 2.7)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	7.5 (± 3.13)	7 (± 2.96)		

D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	6.5 (± 2.94)	4.8 (± 2.46)		
D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)	3.8 (± 2.81)	2.5 (± 2.35)		
D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)	1.9 (± 2.62)	1.4 (± 2.23)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)

End point title	GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)
-----------------	---

End point description:

GMFR of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.17)	1 (± 1.18)	0.9 (± 1.12)	1 (± 1.22)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	3.4 (± 2.91)	5.1 (± 2.78)	1.7 (± 1.81)	2.6 (± 2.78)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				

D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.11)	0.9 (± 1.22)	0.9 (± 1.18)	1 (± 1.67)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	4.2 (± 3.2)	3.7 (± 3.17)	1.6 (± 2.06)	5.9 (± 4.17)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.98)	1 (± 1.12)	1 (± 1.13)	7.4 (± 2.97)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	2.7 (± 3.16)	4.6 (± 2.73)	3.1 (± 2.36)	4.6 (± 2.94)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	4.5 (± 2.94)	5.7 (± 3.01)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	3.6 (± 2.62)	4 (± 2.45)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)

End point title	GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA) ^[17]
-----------------	---

End point description:

GMFR of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 208 and 393

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
D208 (n=30,32)	1.8 (± 2.34)	2.4 (± 2.89)		
D393 (n=30,32)	1.4 (± 2.08)	1.9 (± 2.56)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)

End point title	GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)
-----------------	---

End point description:

GMFR of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.22)	1 (± 1.26)	0.9 (± 1.12)	1 (± 1.18)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	1.5 (± 2.59)	2.3 (± 2.1)	1.3 (± 1.67)	1.3 (± 1.48)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	0.9 (± 1.22)	1 (± 1.09)	0.9 (± 1.47)	1.1 (± 1.91)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	2 (± 2.46)	1.7 (± 1.82)	1.1 (± 1.6)	2.9 (± 3.5)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	1 (± 1.05)	1 (± 1.25)	1 (± 1.06)	2.2 (± 2.48)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	1.6 (± 1.77)	2.5 (± 2.62)	2 (± 2.02)	1.8 (± 2.25)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: titer				
geometric mean (standard deviation)				
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	2.5 (± 2.8)	2.8 (± 2.77)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	1.9 (± 2.3)	2.1 (± 2.25)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)

End point title	GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA) ^[18]
-----------------	---

End point description:

GMFR of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 208 and 393

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
D208 (n=30,32)	1.4 (± 1.93)	1.6 (± 2.1)		
D393 (n=30,32)	1 (± 1.78)	1.4 (± 2.28)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR of Antibody Titers of Strains Not Represented in the Investigational Vaccine: Cross-Protection Assays

End point title	GMFR of Antibody Titers of Strains Not Represented in the Investigational Vaccine: Cross-Protection Assays ^[19]
-----------------	--

End point description:

GMFR of anti-norovirus Cross-Protection Assays: GII.2 EC50, GI.3 EC50 and GII.4.2012 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 56

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
GII.2 EC50	1.1 (± 1.92)	0.8 (± 3.73)		
GI.3 EC50	5.9 (± 3.23)	3 (± 3.36)		
GII.4.2012 EC50	3.2 (± 2.5)	4.1 (± 3.51)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)

End point title	Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)
End point description:	<p>Blocking titers 50 (BT50) of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay. D=Day</p> <p>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.</p>
End point type	Secondary
End point timeframe:	Day 1 (Baseline) and Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	63.7 (± 4.34)	75.1 (± 3.85)	114.7 (± 4.28)	85.8 (± 4.19)
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	63.6 (± 4.31)	72.9 (± 3.95)	113.8 (± 4.02)	83.3 (± 4.05)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	217.3 (± 3.57)	380.7 (± 3.61)	200.3 (± 4.33)	221 (± 3.66)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
------------------	-------------------------------------	-------------------------------------	-----------------------	-----------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	63 (± 4.08)	89.1 (± 4.13)	99.8 (± 4.47)	85 (± 4.64)
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	61.7 (± 4.04)	84.4 (± 4.23)	90.5 (± 4.16)	88 (± 5.49)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	263.7 (± 5.77)	327.5 (± 4.12)	161.5 (± 4.66)	501.4 (± 5.07)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	91.8 (± 4.02)	112.6 (± 3.26)	134.8 (± 3.07)	54 (± 3.95)
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	78.6 (± 4.06)	109 (± 3.25)	130.6 (± 2.95)	400 (± 3.57)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	248.5 (± 4.56)	518.8 (± 3.4)	415.5 (± 4.11)	248.3 (± 4.01)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	81.8 (± 3.86)	93.2 (± 3.75)		
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	366.9 (± 4.6)	534.2 (± 3.17)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	296.5 (± 4.12)	373.4 (± 3.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)

End point title | Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)^[20]

End point description:

Blocking titers 50 (BT50) of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay. D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type | Secondary

End point timeframe:

Days 208 and 393

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
D208 (n=30,32)	113.5 (± 5.03)	202.5 (± 4.06)		
D393 (n=30,32)	88.9 (± 3.9)	160.8 (± 3.96)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)

End point title | Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)

End point description:

Blocking Titers 50 (BT50) of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay. D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type | Secondary

End point timeframe:

Day 1 (Baseline) and Days 28 and 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	29	28	29
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	35 (± 3.86)	26 (± 2.3)	43.3 (± 3.29)	32.4 (± 3.24)
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	32.6 (± 3.49)	24.8 (± 2.29)	42.5 (± 3.1)	31.1 (± 3.12)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	53.5 (± 3.93)	59.3 (± 2.79)	56.7 (± 3.06)	40.6 (± 3.37)

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	28.3 (± 2.45)	37.5 (± 3.18)	29.7 (± 3.34)	28 (± 2.93)
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	26.4 (± 2.44)	36.3 (± 3.09)	25.9 (± 3.08)	30.2 (± 3.87)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	55.5 (± 3.33)	62.1 (± 3.26)	31.2 (± 3.04)	80.6 (± 4.37)

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	24	28
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	32.2 (± 3.09)	28.1 (± 2.31)	32.3 (± 2.79)	21.6 (± 2.11)
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	32.9 (± 3.09)	27.8 (± 2.28)	31.8 (± 2.73)	48 (± 3.37)
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	51.2 (± 3.31)	70.4 (± 3.22)	64.4 (± 3.52)	38.8 (± 2.98)

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	30		
Units: titer				
geometric mean (standard deviation)				
D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	29.7 (± 2.48)	37.3 (± 3.42)		
D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)	75.1 (± 3.35)	104.8 (± 3.35)		
D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)	56.7 (± 3.15)	79.1 (± 3.18)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)

End point title	Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA) ^[21]
-----------------	---

End point description:

Blocking Titers 50 (BT50) of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay. D=Day

Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. "n" in the category is the number of participants with data available at the given time-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 208 and 393

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
D208 (n=30,32)	40.2 (± 3.14)	44.2 (± 3.17)		
D393 (n=30,32)	28.5 (± 2.37)	38.3 (± 2.87)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.2 EC50 (HBGA)

End point title	Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.2 EC50 (HBGA) ^[22]
-----------------	---

End point description:

Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GII.2 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (Baseline) and Day 56

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
Day 1	266.2 (± 2.62)	265.5 (± 4.79)		
Day 56	295.8 (± 2.31)	216.5 (± 4.46)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GI.3 EC50 (HBGA)

End point title	Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GI.3 EC50 (HBGA) ^[23]
-----------------	--

End point description:

Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GI.3 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (Baseline) and Day 56

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
Day 1	59.7 (± 2.98)	74.1 (± 3.7)		
Day 56	350.5 (± 3.05)	222.7 (± 5.09)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.4.2012 EC50 (HBGA)

End point title	Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.4.2012 EC50 (HBGA) ^[24]
-----------------	--

End point description:

Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GII.4.2012 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only. D=Day Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (Baseline) and Day 56

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis is reported for this endpoint.

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (15/50)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	32		
Units: titer				
geometric mean (standard deviation)				
Day 1	45.5 (± 4.07)	50.7 (± 5.1)		
Day 56	146.6 (± 3.11)	208.5 (± 3.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Significant New Medical Conditions

End point title	Percentage of Participants With Significant New Medical Conditions
-----------------	--

End point description:

Significant new medical conditions will be evaluated by the investigator for the co-existence of any of the following conditions: Adverse events of special interest (AESIs) are predefined events for potential immune mediated disorders. All AESIs are medically evaluated to assess if they might indicate an immune-mediated disorder. Immune mediated events (IMEs) are AEs that represent a new diagnosis of a chronic medical condition that was not present or suspected prior to enrollment.

Safety Analysis Set included all participants who received at least one dose of trial vaccine.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to Day 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants number (not applicable)				
AESIs	6.7	3.3	0	6.5
IMEs	0	0	0	0

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants number (not applicable)				
AESIs	0	0	6.7	6.3
IMEs	0	0	0	0

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants number (not applicable)				
AESIs	0	0	0	7.1
IMEs	0	0	0	0

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (not applicable)				
AESIs	3.4	0		
IMEs	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study

End point title	Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study
End point description:	Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participants is unwilling to continue because of the AE. Safety Analysis Set included all participants who received at least one dose of trial vaccine.
End point type	Secondary
End point timeframe:	Day 1 up to Day 56

End point values	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)	GI.1/GII.4 (15/15) - MPL (15)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	30	30	31
Units: percentage of participants				
number (not applicable)	0	0	0	0

End point values	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	31	30	32
Units: percentage of participants				
number (not applicable)	0	0	0	0

End point values	GI.1/GII.4 (50/50)	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
-------------------------	-----------------------	------------------------	--	--------------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	30	29	28
Units: percentage of participants				
number (not applicable)	0	0	0	0

End point values	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: percentage of participants				
number (not applicable)	0	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Unsolicited AEs 28 days after each vaccination (Day 1 to 56) and Serious Adverse Events (SAEs) throughout the trial (Up to Day 393)

Adverse event reporting additional description:

At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.0
--------------------	------

Reporting groups

Reporting group title	GI.1/GII.4 (15/15) - MPL (50)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.

Reporting group title	GI.1/GII.4 (15/50) - MPL (50)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (50/50) - MPL (50)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/15) - MPL (15)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/50) - MPL (15)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (50/50) - MPL (15)
-----------------------	-------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/15)
-----------------------	--------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/50)
-----------------------	--------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (50/50)
-----------------------	--------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (50/150)
-----------------------	---------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/50) - Al(OH)3 (167)
-----------------------	------------------------------------

Reporting group description:

Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.

Reporting group title	GI.1/GII.4 (15/50) x2
-----------------------	-----------------------

Reporting group description:

Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Reporting group title	GI.1/GII.4 (50/150) x2
-----------------------	------------------------

Reporting group description:

Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Reporting group title	GI.1/GII.4 (15/50) - Al(OH)3 (167) x2
-----------------------	---------------------------------------

Reporting group description:

Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.

Serious adverse events	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 30 (6.67%)	0 / 30 (0.00%)	5 / 30 (16.67%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix carcinoma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenocarcinoma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Compression fracture			

subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal polyp			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal polyp			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cholelithiasis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Major depression			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	1 / 30 (3.33%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Chondropathy			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			

subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leptospirosis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	1 / 30 (3.33%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal abscess			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events

GI.1/GII.4 (15/15) -

GI.1/GII.4 (15/50) -

GI.1/GII.4 (50/50) -

	MPL (15)	MPL (15)	MPL (15)
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 31 (6.45%)	1 / 30 (3.33%)	0 / 31 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix carcinoma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenocarcinoma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Compression fracture			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain upper			

subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal polyp			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal polyp			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Major depression			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			

subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Chondropathy			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 31 (0.00%)	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	1 / 31 (3.23%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Leptospirosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal abscess			
subjects affected / exposed	1 / 31 (3.23%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)	GI.1/GII.4 (50/50)
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 30 (10.00%)	3 / 32 (9.38%)	1 / 29 (3.45%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix carcinoma			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenocarcinoma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Compression fracture			

subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal polyp			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal polyp			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cholelithiasis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Major depression			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Chondropathy			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			

subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leptospirosis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal abscess			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events

GI.1/GII.4 (50/150)

GI.1/GII.4 (15/50) -

GI.1/GII.4 (15/50)

		Al(OH) ₃ (167)	x2
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 30 (3.33%)	1 / 29 (3.45%)	2 / 28 (7.14%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix carcinoma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenocarcinoma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	1 / 28 (3.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Compression fracture			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain upper			

subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal polyp			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal polyp			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Major depression			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	1 / 28 (3.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			

subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Chondropathy			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 29 (3.45%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	1 / 30 (3.33%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Leptospirosis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal abscess			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167) x2	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 29 (3.45%)	1 / 31 (3.23%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix carcinoma			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Compression fracture			

subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon injury			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 29 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal polyp			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cholelithiasis			
subjects affected / exposed	0 / 29 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Major depression			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Chondropathy			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			

subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leptospirosis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis aseptic			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal abscess			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	GI.1/GII.4 (15/15) - MPL (50)	GI.1/GII.4 (15/50) - MPL (50)	GI.1/GII.4 (50/50) - MPL (50)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 30 (33.33%)	12 / 30 (40.00%)	7 / 30 (23.33%)
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 30 (10.00%)	8 / 30 (26.67%)	3 / 30 (10.00%)
occurrences (all)	5	10	4
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 30 (6.67%)	2 / 30 (6.67%)	2 / 30 (6.67%)
occurrences (all)	3	3	2
Influenza like illness			
subjects affected / exposed	0 / 30 (0.00%)	0 / 30 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Injection site pain			
subjects affected / exposed	0 / 30 (0.00%)	2 / 30 (6.67%)	1 / 30 (3.33%)
occurrences (all)	0	2	2
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 30 (0.00%)	1 / 30 (3.33%)	1 / 30 (3.33%)
occurrences (all)	0	1	2
Diarrhoea			
subjects affected / exposed	1 / 30 (3.33%)	3 / 30 (10.00%)	0 / 30 (0.00%)
occurrences (all)	1	3	0
Nausea			
subjects affected / exposed	2 / 30 (6.67%)	2 / 30 (6.67%)	0 / 30 (0.00%)
occurrences (all)	2	2	0
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal Pain			
subjects affected / exposed	1 / 30 (3.33%)	3 / 30 (10.00%)	1 / 30 (3.33%)
occurrences (all)	1	3	1
Infections and infestations			
Nasopharyngitis			

subjects affected / exposed	3 / 30 (10.00%)	3 / 30 (10.00%)	3 / 30 (10.00%)
occurrences (all)	5	3	3

Non-serious adverse events	GI.1/GII.4 (15/15) - MPL (15)	GI.1/GII.4 (15/50) - MPL (15)	GI.1/GII.4 (50/50) - MPL (15)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 31 (32.26%)	9 / 30 (30.00%)	9 / 31 (29.03%)
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 31 (9.68%)	3 / 30 (10.00%)	3 / 31 (9.68%)
occurrences (all)	3	3	3
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 31 (3.23%)	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	1	2	0
Influenza like illness			
subjects affected / exposed	1 / 31 (3.23%)	0 / 30 (0.00%)	3 / 31 (9.68%)
occurrences (all)	1	0	3
Injection site pain			
subjects affected / exposed	0 / 31 (0.00%)	0 / 30 (0.00%)	2 / 31 (6.45%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 31 (6.45%)	2 / 30 (6.67%)	1 / 31 (3.23%)
occurrences (all)	4	2	1
Diarrhoea			
subjects affected / exposed	2 / 31 (6.45%)	2 / 30 (6.67%)	1 / 31 (3.23%)
occurrences (all)	2	2	1
Nausea			
subjects affected / exposed	0 / 31 (0.00%)	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	0	4	0
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal Pain			
subjects affected / exposed	2 / 31 (6.45%)	3 / 30 (10.00%)	1 / 31 (3.23%)
occurrences (all)	2	3	1
Infections and infestations			

Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 30 (0.00%) 0	0 / 31 (0.00%) 0
Non-serious adverse events	GI.1/GII.4 (15/15)	GI.1/GII.4 (15/50)	GI.1/GII.4 (50/50)
Total subjects affected by non-serious adverse events subjects affected / exposed	7 / 30 (23.33%)	11 / 32 (34.38%)	8 / 29 (27.59%)
Nervous system disorders Headache subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 32 (0.00%) 0	1 / 29 (3.45%) 2
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 32 (3.13%) 1	0 / 29 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 32 (3.13%) 1	0 / 29 (0.00%) 0
Injection site pain subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 32 (0.00%) 0	2 / 29 (6.90%) 2
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 32 (0.00%) 0	1 / 29 (3.45%) 1
Diarrhoea subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 4	2 / 32 (6.25%) 2	1 / 29 (3.45%) 2
Nausea subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	2 / 32 (6.25%) 2	2 / 29 (6.90%) 2
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	3 / 32 (9.38%) 3	0 / 29 (0.00%) 0
Infections and infestations			

Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	2 / 32 (6.25%) 2	1 / 29 (3.45%) 1
Non-serious adverse events	GI.1/GII.4 (50/150)	GI.1/GII.4 (15/50) - Al(OH) ₃ (167)	GI.1/GII.4 (15/50) x2
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 30 (20.00%)	6 / 29 (20.69%)	9 / 28 (32.14%)
Nervous system disorders Headache subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	4 / 29 (13.79%) 4	2 / 28 (7.14%) 2
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 29 (0.00%) 0	1 / 28 (3.57%) 1
Influenza like illness subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 29 (0.00%) 0	0 / 28 (0.00%) 0
Injection site pain subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 29 (0.00%) 0	1 / 28 (3.57%) 1
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 29 (0.00%) 0	0 / 28 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 29 (0.00%) 0	3 / 28 (10.71%) 3
Nausea subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 29 (3.45%) 1	2 / 28 (7.14%) 2
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	3 / 29 (10.34%) 3	1 / 28 (3.57%) 1
Infections and infestations			

Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	1 / 29 (3.45%) 1	1 / 28 (3.57%) 1
---	---------------------	---------------------	---------------------

Non-serious adverse events	GI.1/GII.4 (50/150) x2	GI.1/GII.4 (15/50) - Al(OH)3 (167) x2	
Total subjects affected by non-serious adverse events subjects affected / exposed	8 / 29 (27.59%)	9 / 31 (29.03%)	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	2 / 31 (6.45%) 2	
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 31 (0.00%) 0	
Influenza like illness subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	1 / 31 (3.23%) 1	
Injection site pain subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	0 / 31 (0.00%) 0	
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 31 (6.45%) 4	
Diarrhoea subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 2	1 / 31 (3.23%) 1	
Nausea subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	1 / 31 (3.23%) 1	
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	1 / 31 (3.23%) 1	
Infections and infestations			

Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	2 / 31 (6.45%) 2	
---	---------------------	---------------------	--

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 January 2014	Substantial amendment due to input from regulatory authorities, to exclude participants aged 17 years, and to clarify who will perform unblinded Day 56 and Day 208 analyses and who will remain blinded until after the database lock at Day 393.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported